Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins
AM Almeida, JA Queiroz, F Sousa, Â Sousa - Drug discovery today, 2019 - Elsevier
Highlights•Human papillomavirus (HPV) has a primordial role in the development of cervical
cancer.•Therapies currently available for cervical cancer treatment are reviewed.•The …
cancer.•Therapies currently available for cervical cancer treatment are reviewed.•The …
[HTML][HTML] Recent advances in the management of anal cancer
Anal cancer is a rare condition, although its incidence has been increasing over the past
several decades, particularly in women. The majority of anal cancers are squamous cell …
several decades, particularly in women. The majority of anal cancers are squamous cell …
Regulatory considerations on the development of mRNA vaccines
R Naik, K Peden - mRNA Vaccines, 2020 - Springer
Developing traditional viral vaccines for infectious diseases usually takes years, as these
are usually produced either by chemical inactivation of the virus or attenuation of the …
are usually produced either by chemical inactivation of the virus or attenuation of the …
Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis
R Ivancic, H Iqbal, B Desilva, Q Pan… - Clinical & Experimental …, 2020 - academic.oup.com
Recurrent respiratory papillomatosis (RRP) is characterized by benign exophytic lesions of
the respiratory tract caused by the human papillomavirus (HPV), in particular low-risk HPV6 …
the respiratory tract caused by the human papillomavirus (HPV), in particular low-risk HPV6 …
Human papillomavirus E5 protein, the undercover culprit of tumorigenesis
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract
worldwide. It has been well documented that the HPV oncoproteins E6 and E7 play …
worldwide. It has been well documented that the HPV oncoproteins E6 and E7 play …
Recurrent respiratory papillomatosis: update 2018
CS Derkay, AE Bluher - Current opinion in otolaryngology & head …, 2018 - journals.lww.com
RRP is declining in incidence but remains a challenging disease to treat with great costs to
patients, families, and the healthcare system. As the disease continues to be better …
patients, families, and the healthcare system. As the disease continues to be better …
Calreticulin as an Adjuvant In Vivo to Promote Dendritic Cell Maturation and Enhance Antigen‐Specific T Lymphocyte Responses against Melanoma
Z Gong, M Chen, J Miao, CJ Han… - Journal of …, 2022 - Wiley Online Library
An endoplasmic reticulum resident protein, calreticulin (CRT), participates in many cellular
processes. CRT is a tumor‐associated antigen with an important role in antitumor immunity …
processes. CRT is a tumor‐associated antigen with an important role in antitumor immunity …
Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis
Y Yiu, S Fayson, H Smith… - Annals of Otology …, 2019 - journals.sagepub.com
Objectives: To investigate vaccine compliance and clinical outcomes after implementation of
an initiative to provide the human papillomavirus (HPV) vaccine to all patients with recurrent …
an initiative to provide the human papillomavirus (HPV) vaccine to all patients with recurrent …
Pharmacotherapy for recurrent respiratory papillomatosis (RRP): a treatment update
AJ Donne, A Kinshuck - Expert Opinion on Pharmacotherapy, 2021 - Taylor & Francis
Introduction: Recurrent respiratory papillomatosis is a rare human papillomavirus (HPV)-
induced condition where warts grow within the airway and especially the larynx to effect …
induced condition where warts grow within the airway and especially the larynx to effect …
VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal …
J Feliu, R Garcia‐Carbonero, J Capdevila… - Cancer …, 2020 - Wiley Online Library
Aim VITAL, a phase II single‐arm study, aimed to evaluate efficacy and safety of
panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy (RT) …
panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy (RT) …